Trials / Terminated
TerminatedNCT00334646
Cyclophosphamide Drug Interaction Study In Cancer Patients
An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral GW679769 | 150mg oral, once daily on days 1-3 |
| DRUG | IV Cyclophosphamide 500-700mg/m2 | IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle |
Timeline
- Start date
- 2005-08-10
- Primary completion
- 2009-10-14
- Completion
- 2009-10-14
- First posted
- 2006-06-08
- Last updated
- 2017-11-17
Locations
5 sites across 3 countries: United States, New Zealand, Sweden
Source: ClinicalTrials.gov record NCT00334646. Inclusion in this directory is not an endorsement.